Icatibant
Back to searchMolecule Structure
Scientific Name
Icatibant
Description of the Drug
Icatibant is a bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06196
http://www.drugbank.ca/drugs/DB06196
Brand Name(s)
Not Available
Company Owner(s)
Teva Pharmaceuticals Usa Inc, Cipla Ltd, Fresenius Kabi Usa Llc, Takeda Pharmaceuticals Usa Inc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Nang Kuang Pharmaceutical Co Ltd, Dr Reddys Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Slayback Pharma Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Bradykinin B2 receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL3157 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL21495177 | ||
| DrugBank | DB06196 | ||
| PubChem: Thomson Pharma | 14890591 | 14841954 | |
| PubChem | 6918173 | ||
| Nikkaji | J389.307C | ||
| BindingDB | 50406750 | 50403371 | |
| EPA CompTox Dashboard | DTXSID20903963 | ||
| DrugCentral | 4186 | ||
| ChemicalBook | CB1318492 | ||
| rxnorm | FIRAZYR | ICATIBANT ACETATE | ICATIBANT |
| ChEBI | 68556 |
